N@N

Alimera Sciences To Present At Oppenheimer 23rd Annual Healthcare Conference

_{//health-fitness.news-articles.net/content/2012/ .. penheimer-23rd-annual-healthcare-conference.html}
^{Published in Health and Fitness on Monday, December 3rd 2012 at 7:15 GMT by Market Wire}  

Alimera Sciences To Present At Oppenheimer 23rd Annual Healthcare Conference -- ATLANTA, Dec. 3, 2012 /PRNewswire/ --

ATLANTA, Dec. 3, 2012 /PRNewswire/ -- Alimera Sciences, Inc. (Nasdaq: [ ALIM ]) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that Dan Myers, president and chief executive officer, will present at the Oppenheimer 23^rd Annual Healthcare Conference at 4:30 P.M. ET on Wednesday, December 12, 2012 at The Waldorf Astoria Hotel in New York City.

The presentation will be webcast live and can be accessed on the Investor Relations section of the corporate website at [ http://www.alimerasciences.com ]. For those who are not available to listen to the live broadcast, the webcast will be archived for 90 days.

About Alimera Sciences, Inc.

Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Alimera Sciences Limited, based in London, is headquarters of the company's European operations. Presently Alimera is focused on diseases affecting the back of the eye, or retina. Its primary product, ILUVIEN, is an intravitreal implant containing fluocinolone acetonide (FAc), a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease.

SOURCE Alimera Sciences, Inc.